Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05212377 in Alzheimer's disease with neuropsychiatric symptoms
NCT01712074Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of PF-05212377 in Alzheimer's disease (AD), sponsored by Pfizer. Started Nov 2012; status: terminated.
02
Drugs
PF-05212377
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01712074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712074.